Estrella Biopharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2022-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.estrellabio.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1
Recruiting
- Conditions
- Lymphoma, Non-HodgkinsLymphomas Non-Hodgkin's B-CellLarge B-Cell LymphomaRelapsed Non-Hodgkin LymphomaB-Cell Non-Hodgkin's Lymphoma (NHL)Lymphoma, Non-HodgkinCNS LymphomaNon-Hodgkin LymphomaLymphomaRefractory B-Cell Non-Hodgkin Lymphoma
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Estrella Biopharma, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06343311
- Locations
- 🇺🇸
University of California, Davis, Sacramento, California, United States
News
No news found